Immatics Biotechnologies GmbH has appointed Stephen Eck as chief medical officer to help advance the company’s portfolio of immunotherapies against cancer. Dr Eck joins the German company from Astellas Pharma Inc where he was global head of oncology medical sciences. Prior to this he held senior roles at Pfizer Inc and Eli Lilly and Company.
Dr Eck has a PhD in chemistry from Harvard University and a MD degree from the University of Mississippi School of Medicine in the US.
Immatics announced the appointment on 14 May 2018.
Copyright 2018 Evernow Publishing Ltd.